Phare Bio, a social-impact biotech combating antibiotic resistance with AI, today announced selection for the Google.org Accelerator: Generative AI, gaining a share of $30 million and six months of pro-bono technical support. Built with MIT’s Collins Lab, Phare’s open-access platform uses generative models and biological screening to design new antibiotic classes and aims to deliver 15 pre-clinical candidates by 2030.
CEO Dr. Akhila Kosaraju said the backing “ensures our tools leave the lab and empower researchers worldwide to accelerate discoveries.” Karla Palmer, Manager for AI & Scientific Progress at Google.org, said the platform “can catalyze a new era of collaboration against antibiotic-resistant infections.”
